title: Clopidogrel and CYP2C19 testing: ready for clinical prime time?
authors.affiliation: Cardiovascular Research Center, Mount Sinai School of Medicine, New York, NY, USA.
authors.forename: Jean-Sébastien
authors.initials: JS
authors.lastname: Hulot
authors.forename: Roger
authors.initials: R
authors.lastname: Hajjar
authors.forename: Gilles
authors.initials: G
authors.lastname: Montalescot
mesh_terms: D054058:Acute Coronary Syndrome / Q000188:drug therapy / Q000235:genetics; D001189:Aryl Hydrocarbon Hydroxylases / Q000235:genetics / Q000502:physiology*; D000077144:Clopidogrel; D065731:Cytochrome P-450 CYP2C19; D005820:Genetic Testing; D005838:Genotype; D006579:Heterozygote; D006801:Humans; D011110:Polymorphism, Genetic; D058921:Purinergic P2Y Receptor Antagonists / Q000627:therapeutic use*; D013988:Ticlopidine / Q000031:analogs & derivatives* / Q000627:therapeutic use
chemical_list: D058921:Purinergic P2Y Receptor Antagonists; D000077144:Clopidogrel; D001189:Aryl Hydrocarbon Hydroxylases; C045793:CYP2C19 protein, human; D065731:Cytochrome P-450 CYP2C19; D013988:Ticlopidine